HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

AB&B BIO-TECH-B

46.580

-1.620-3.36%

Volume:220.60K

Turnover:10.31M

Market Cap:18.33B

PE:-59.21

High:47.560

Open:47.280

Low:46.000

Close:48.200

52wk High:59.600

52wk Low:33.000

Shares:393.44M

HK Float Shares:296.36M

Volume Ratio:0.92

T/O Rate:0.07%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.787

ROE:--

ROA:--

PB:269.26

PE(LYR):-59.21

PS:64.46

Loading ...

Overview Company News Filings

Hong Kong Stock Market Preview | Fed Beige Book Shows Employment Levels Generally Stable, September Rate Cut Probability at 96.6%

Ab&B Bio-Tech's Influenza Vaccine Application Gets China Nod

MT Newswires Live

AB&B Bio-Tech Co. Ltd. JS Secures NMPA Approval for China's First Quadrivalent Subunit Influenza Vaccine

AB&B BIO-TECH-B (02627): Marketing Application for Quadrivalent Influenza Virus Subunit Vaccine Approved by National Medical Products Administration

Ab&B Bio Tech Co Ltd Js - Approval of Application for Quadrivalent Subunit Influenza Vaccine by China's Nmpa

THOMSON REUTERS

Interim Report Shows Revenue Surge of Over 900% YoY: Examining the "Investment Certainty" Behind AB&B BIO-TECH-B's (02627) Core Innovation Technology

Hong Kong Stock Movement | AB&B BIO-TECH-B (02627) Closes Up 1.35% with Interim Revenue Surging Over 9 Times Year-on-Year

AB&B BIO-TECH-B (02627) Reports Interim Results with Revenue of RMB 71.12 Million, Surging 919.25% Year-on-Year

AB&B Bio-Tech Co. Ltd. JS Reports 919% Surge in Revenue to RMB 71.1 Million for H1 2025, Narrows Loss to RMB 121.5 Million, EPS at RMB (0.34)

Ab&B Bio Tech Co Ltd Js - Hy Loss RMB121.5 Mln

THOMSON REUTERS

Hong Kong Stock Alert | AB&B BIO-TECH-B (02627) Surges Over 7% as Recombinant RSV Vaccine Receives IND Approval in Both China and US

Investment Decision Reference: Hang Seng Index Shows Higher Probability of Upward Movement

AB&B BIO-TECH-B (02627): IND Approval Granted by China's CDE and US FDA for Recombinant RSV Vaccine (CHO Cell) with Adjuvant

BRIEF-AB&B Says China CDE, U.S. FDA Approve IND Application Of Co's RSV Vaccine

Ab&B Says China Cde, U.S. FDA Approve Investigational New Drug Application of Co's Recombinant Rsv Vaccine

THOMSON REUTERS

Hong Kong IPO Weekly Report: 18A Biotech IPO Wave Returns! AB&B BIO-TECH-B and INNOGEN-B Surge on Debut

HK Movers | Biotech Shares Soar. PegBio up 35%; Ascletis up 11%; TYK Medicines up 9%

Tiger Newspress

HK Movers | HK's Biotech Shares Soar. CANbridge up 29%; Ab&B Bio-Tech up 26%; Abbisko up 7%

Tiger Newspress

Stock Track | AB&B Bio-Tech Soars 35% as Flagship Flu Vaccine Shortlisted for China's Insurance Coverage

AB&B Bio-Tech's Flu Vaccine Shortlisted for Insurance Coverage in China

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/02627/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02627","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02627\",,,,,undefined,":{"symbol":"02627","market":"HK","secType":"STK","nameCN":"AB&B BIO-TECH-B","latestPrice":46.58,"timestamp":1757404786518,"preClose":48.2,"halted":0,"volume":220600,"delay":0,"floatShares":296361845,"shares":393442600,"eps":-0.7866825463601175,"marketStatus":"Closed","change":-1.62,"latestTime":"09-09 15:59:46","open":47.28,"high":47.56,"low":46,"amount":10314786,"amplitude":0.032365,"askPrice":46.58,"askSize":200,"bidPrice":46.56,"bidSize":1400,"shortable":0,"etf":0,"ttmEps":-0.8596175216944321,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1757467800000},"marketStatusCode":5,"adr":0,"listingDate":1754841600000,"exchange":"SEHK","adjPreClose":48.2,"openAndCloseTimeList":[[1757381400000,1757390400000],[1757394000000,1757404800000]],"volumeRatio":0.918707,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02627\",,,,,undefined,":{"symbol":"02627","floatShares":296361845,"roa":"--","roe":"--","lyrEps":-0.786683,"volumeRatio":0.918707,"shares":393442600,"dividePrice":0,"high":47.56,"amplitude":0.032365,"preClose":48.2,"low":46,"week52Low":33,"pbRate":"269.26","psRate":"64.46","week52High":59.6,"institutionHeld":0,"latestPrice":46.58,"committee":0.75,"eps":-0.7866825463601175,"divideRate":0,"volume":220600,"delay":0,"ttmEps":-0.8596175216944321,"open":47.28,"prevYearClose":12.9,"prevWeekClose":49.22,"prevMonthClose":51,"prevQuarterClose":12.9,"fiveDayClose":48.66,"twentyDayClose":43.7,"sixtyDayClose":12.9},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02627\",params:#limit:5,,,undefined,":[{"date":"2025-08-28","symbol":"02627","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756344600000,"name":null,"time":"","dateTimestamp":1756310400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02627\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02627\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02627\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02627","date":"2025-09-08","current":-61.371907,"percent":0.761905,"low":-68.430715,"twenty":-66.383222,"median":-63.829854,"eighty":-60.398722,"high":-18.07815,"avg":-60.789086,"sd":10.803254,"marketCap":18963933320},"quantilePoints":[{"date":"2025-08-08","current":-18.07815,"twenty":-18.07815,"median":-18.07815,"eighty":-18.07815,"marketCap":5586884920},{"date":"2025-08-15","current":-60.155426,"twenty":-60.155426,"median":-56.438909,"eighty":-42.414982,"marketCap":18562621868},{"date":"2025-08-22","current":-65.870069,"twenty":-65.897052,"median":-63.746879,"eighty":-55.654938,"marketCap":20262293900},{"date":"2025-08-29","current":-64.920623,"twenty":-66.830053,"median":-65.395346,"eighty":-57.22288,"marketCap":20065572600},{"date":"2025-09-05","current":-62.716917,"twenty":-66.416243,"median":-63.912829,"eighty":-60.155426,"marketCap":19365244772},{"date":"2025-09-08","current":-61.371907,"twenty":-66.383222,"median":-63.829854,"eighty":-60.398722,"marketCap":18963933320}],"updateTime":1757413879745},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02627\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1142605337","title":"Hong Kong Stock Market Preview | Fed Beige Book Shows Employment Levels Generally Stable, September Rate Cut Probability at 96.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1142605337","media":"Stock News","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142605337?lang=en_us&edition=fundamental","pubTime":"2025-09-04 07:43","pubTimestamp":1756942981,"startTime":"0","endTime":"0","summary":"**Today's Headlines** Fed Beige Book Shows Employment Levels Generally Stable, September Rate Cut Probability at 96.6% The Federal Reserve's Beige Book indicated that eleven districts reported...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YANG","BK1536","IVV","BK4581","SPY","BK1161","BK1183","OEF","SDS","SH","HSTECH","09880","09863","BK1613","BK4614",".SPX","SPXU","HSCEI","OEX","02627","BK1119","07226","BK4550","BK4559","MESmain","BK1152","00315","BK4585","SSO","BK4504","ESmain","BK4588","UPRO","BK4534"],"gpt_icon":1},{"id":"2564398090","title":"Ab&B Bio-Tech's Influenza Vaccine Application Gets China Nod","url":"https://stock-news.laohu8.com/highlight/detail?id=2564398090","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564398090?lang=en_us&edition=fundamental","pubTime":"2025-09-03 19:43","pubTimestamp":1756899811,"startTime":"0","endTime":"0","summary":"Ab&B Bio-Tech's (HKG:2627) new drug application for the quadrivalent subunit influenza vaccine for individuals aged six to 35 months was approved by China's National Medical Products Administration, a Wednesday Hong Kong bourse filing said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02627"],"gpt_icon":0},{"id":"2564643483","title":"AB&B Bio-Tech Co. Ltd. JS Secures NMPA Approval for China's First Quadrivalent Subunit Influenza Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2564643483","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564643483?lang=en_us&edition=fundamental","pubTime":"2025-09-03 17:59","pubTimestamp":1756893552,"startTime":"0","endTime":"0","summary":"AB&B Bio-Tech Co. Ltd. JS has received regulatory approval from the National Medical Products Administration  of the People's Republic of China for its new quadrivalent subunit influenza vaccine. This vaccine, designed for individuals aged 6 to 35 months, represents the first and only quadrivalent subunit influenza vaccine approved in China for all age groups at full dosage level. The product offers comprehensive protection, high antigen purity, and low risks of adverse reactions. The company, focused on innovative vaccine development, aims to replace traditional and imported vaccines in China and expand into international markets. Shareholders and potential investors are advised to exercise caution when dealing with the company's securities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDL8mynwc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","BK1161"],"gpt_icon":0},{"id":"1101919233","title":"AB&B BIO-TECH-B (02627): Marketing Application for Quadrivalent Influenza Virus Subunit Vaccine Approved by National Medical Products Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=1101919233","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101919233?lang=en_us&edition=fundamental","pubTime":"2025-09-03 17:40","pubTimestamp":1756892433,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (02627) announced that the company's board of directors is pleased to announce that China's National Medical Products Administration (NMPA) has approved the group's new drug...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159646","BK1161","02627"],"gpt_icon":0},{"id":"2564855361","title":"Ab&B Bio Tech Co Ltd Js - Approval of Application for Quadrivalent Subunit Influenza Vaccine by China's Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2564855361","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564855361?lang=en_us&edition=fundamental","pubTime":"2025-09-03 17:34","pubTimestamp":1756892069,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nFWN3UQ01A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02627","BK1161"],"gpt_icon":0},{"id":"1104271548","title":"Interim Report Shows Revenue Surge of Over 900% YoY: Examining the \"Investment Certainty\" Behind AB&B BIO-TECH-B's (02627) Core Innovation Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1104271548","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104271548?lang=en_us&edition=fundamental","pubTime":"2025-08-28 20:14","pubTimestamp":1756383248,"startTime":"0","endTime":"0","summary":"According to Goldman Sachs' latest macro assessment released in August, market expectations for a Federal Reserve rate cut in September are heating up, potentially attracting more global capital into...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","BK1161"],"gpt_icon":0},{"id":"1159501544","title":"Hong Kong Stock Movement | AB&B BIO-TECH-B (02627) Closes Up 1.35% with Interim Revenue Surging Over 9 Times Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1159501544","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159501544?lang=en_us&edition=fundamental","pubTime":"2025-08-28 19:00","pubTimestamp":1756378858,"startTime":"0","endTime":"0","summary":"On August 28, AB&B BIO-TECH-B (02627) showed active performance in late trading with its stock price surging rapidly. The stock closed up 1.35% at HK$52.5. After market close on the same day, AB&B...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","BK1161"],"gpt_icon":0},{"id":"1133141248","title":"AB&B BIO-TECH-B (02627) Reports Interim Results with Revenue of RMB 71.12 Million, Surging 919.25% Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1133141248","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133141248?lang=en_us&edition=fundamental","pubTime":"2025-08-28 16:52","pubTimestamp":1756371144,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (02627) announced its interim results for the six months ended June 30, 2025, reporting group revenue of RMB 71.123 million, representing a substantial increase of 919.25%...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","BK1161"],"gpt_icon":0},{"id":"2562708950","title":"AB&B Bio-Tech Co. Ltd. JS Reports 919% Surge in Revenue to RMB 71.1 Million for H1 2025, Narrows Loss to RMB 121.5 Million, EPS at RMB (0.34)","url":"https://stock-news.laohu8.com/highlight/detail?id=2562708950","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562708950?lang=en_us&edition=fundamental","pubTime":"2025-08-28 16:35","pubTimestamp":1756370147,"startTime":"0","endTime":"0","summary":"AB&B Bio-Tech Co. Ltd. JS Reports 919% Surge in Revenue to RMB 71.1 Million for H1 2025, Narrows Loss to RMB 121.5 Million, EPS at RMB . Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB&B Bio-Tech Co. Ltd. JS published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nNDL6YSTmH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627"],"gpt_icon":0},{"id":"2562089814","title":"Ab&B Bio Tech Co Ltd Js -  Hy Loss RMB121.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2562089814","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562089814?lang=en_us&edition=fundamental","pubTime":"2025-08-28 16:32","pubTimestamp":1756369971,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nFWN3UJ17N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02627"],"gpt_icon":0},{"id":"1163377062","title":"Hong Kong Stock Alert | AB&B BIO-TECH-B (02627) Surges Over 7% as Recombinant RSV Vaccine Receives IND Approval in Both China and US","url":"https://stock-news.laohu8.com/highlight/detail?id=1163377062","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163377062?lang=en_us&edition=fundamental","pubTime":"2025-08-18 09:48","pubTimestamp":1755481694,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (02627) surged over 7%. As of press time, the stock climbed 7.25% to HK$50.6, with a turnover of HK$136.446 million. On the news front, AB&B BIO-TECH-B announced that the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","159646"],"gpt_icon":1},{"id":"1162935143","title":"Investment Decision Reference: Hang Seng Index Shows Higher Probability of Upward Movement","url":"https://stock-news.laohu8.com/highlight/detail?id=1162935143","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162935143?lang=en_us&edition=fundamental","pubTime":"2025-08-18 09:24","pubTimestamp":1755480285,"startTime":"0","endTime":"0","summary":"**Market Commentary** The market has been pricing in interest rate cuts in advance, while domestic personal loan subsidy policies are also helping drive capital actively into the market. With leading...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00968","HSI","YANG","02627","HSImain","06865","MHImain","LU1983299162.USD","MCHmain","BK1169","03800","BK4614","BK1610","BK1589","02833","BK1594","IE00BZ08YS42.EUR","SG9999014674.SGD","HHImain","513600","IE00BZ08YR35.GBP","BK1554","IE00BZ08YT58.USD"],"gpt_icon":1},{"id":"1156243565","title":"AB&B BIO-TECH-B (02627): IND Approval Granted by China's CDE and US FDA for Recombinant RSV Vaccine (CHO Cell) with Adjuvant","url":"https://stock-news.laohu8.com/highlight/detail?id=1156243565","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156243565?lang=en_us&edition=fundamental","pubTime":"2025-08-17 19:30","pubTimestamp":1755430227,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (02627) announced that its self-developed recombinant respiratory syncytial virus vaccine (CHO cell) with adjuvant has received Investigational New Drug (IND) approval from China's...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4017","159646","LU1223083913.SGD","02627","LU1223082519.USD","CDE","LU1223082196.USD"],"gpt_icon":1},{"id":"2560922542","title":"BRIEF-AB&B Says China CDE, U.S. FDA Approve IND Application Of Co's RSV Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2560922542","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560922542?lang=en_us&edition=fundamental","pubTime":"2025-08-17 19:25","pubTimestamp":1755429903,"startTime":"0","endTime":"0","summary":"BRIEF-AB&B Says China CDE, U.S. FDA Approve IND Application Of Co's RSV VaccineAug 17  - Ab&B Bio Tech Co Ltd JS 2627.HK:SAYS CHINA CDE, U.S. FDA APPROVE INVESTIGATIONAL NEW DRUG   APPLICATION OF CO'S RECOMBINANT RSV VACCINESource textFurther company coverage: 2627.HK  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250817:nL4N3U9024:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627"],"gpt_icon":0},{"id":"2560541922","title":"Ab&B  Says China Cde, U.S. FDA Approve Investigational New Drug Application of Co's Recombinant Rsv Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2560541922","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560541922?lang=en_us&edition=fundamental","pubTime":"2025-08-17 19:25","pubTimestamp":1755429903,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250817:nL4N3U9024:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02627"],"gpt_icon":0},{"id":"1128488469","title":"Hong Kong IPO Weekly Report: 18A Biotech IPO Wave Returns! AB&B BIO-TECH-B and INNOGEN-B Surge on Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=1128488469","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128488469?lang=en_us&edition=fundamental","pubTime":"2025-08-17 17:41","pubTimestamp":1755423679,"startTime":"0","endTime":"0","summary":"Since the beginning of 2025, Hong Kong's stock market has seen 53 new IPOs (plus 1 De-SPAC and 1 introduction listing), raising a total of approximately HK$130.22 billion. In the most recent week...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07226","YANG","02627","HSCEI","02591","HSTECH","BK4614"],"gpt_icon":0},{"id":"1168554344","title":"HK Movers | Biotech Shares Soar. PegBio up 35%; Ascletis up 11%; TYK Medicines up 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1168554344","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168554344?lang=en_us&edition=fundamental","pubTime":"2025-08-15 10:20","pubTimestamp":1755224445,"startTime":"0","endTime":"0","summary":"Hong Kong’s biotech stocks rose on Friday.PegBio rose 35%; Ascletis rose 11%; TYK Medicines rose 9%; Ab&B Bio-Tech, JW Therapeutics rose 5%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"b596819316a65b7eebee6f2210b3d5a1","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","02565","02410","02627"],"gpt_icon":0},{"id":"1114179393","title":"HK Movers | HK's Biotech Shares Soar. CANbridge up 29%; Ab&B Bio-Tech up 26%; Abbisko up 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1114179393","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114179393?lang=en_us&edition=fundamental","pubTime":"2025-08-13 10:42","pubTimestamp":1755052965,"startTime":"0","endTime":"0","summary":"Hong Kong’s biotech stocks rose on Wednesday.CANbridge rose 29%; Ab&B Bio-Tech rose 26%; Abbisko soared 7%; WuXi XDC rose 6%; Asymchem, JOINN rose 5%.Ab&B Bio-Tech soared 158% in its trading debut in...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"eea96c2db952be4ad0141d428041d6b9","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256","02627","01228","02268","06127"],"gpt_icon":1},{"id":"1130107646","title":"Stock Track | AB&B Bio-Tech Soars 35% as Flagship Flu Vaccine Shortlisted for China's Insurance Coverage","url":"https://stock-news.laohu8.com/highlight/detail?id=1130107646","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130107646?lang=en_us&edition=fundamental","pubTime":"2025-08-13 09:52","pubTimestamp":1755049962,"startTime":"0","endTime":"0","summary":"AB&B Bio-Tech (HKG:02627) saw its stock price skyrocket by 35.01% in intraday trading on Wednesday, following a significant announcement regarding its flagship flu vaccine. The Hong Kong-listed...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"eea96c2db952be4ad0141d428041d6b9","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02627"],"gpt_icon":1},{"id":"2559673466","title":"AB&B Bio-Tech's Flu Vaccine Shortlisted for Insurance Coverage in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2559673466","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559673466?lang=en_us&edition=fundamental","pubTime":"2025-08-13 09:46","pubTimestamp":1755049583,"startTime":"0","endTime":"0","summary":"AB&B Bio-Tech  said Chinese authorities have placed its flagship flu vaccine on a preliminary list for possible insurance coverage, according to a Hong Kong bourse filing Wednesday.The company's quadrivalent subunit influenza vaccine, Huierkangxin, made it to the National Healthcare Security Administration's preliminary list for insurance reimbursement and was the only product of its kind to do so, AB&B Bio-Tech said.Huierkangxin remains the first and only quadrivalent subunit influenza vaccine to be approved in China as of July 21, AB&B Bio-Tech said.Shares of the pharmaceutical company jumped 13% in Wednesday morning trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02627"],"gpt_icon":1}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":31,"code":"91000000","status":"200"}]}}